B
샤페론
378800KOSDAQ58.0 / 100
Reference Date: 2026-10-23
Financial Score20.5 / 40
News Sentiment12.5 / 25
Momentum15.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Surged 351.0% over the past month, with no recent news.
Company InformationBased on 2025 Annual Report
Business Overview
Shapieron is a biotech venture specializing in drug development, leveraging its platform targeting GPCR19 to inhibit inflammatory complexes. The company is conducting clinical trials for COVID-19 and Alzheimer's treatments, while expanding into ADC and RPT-based nanobody development. It has established a U.S. subsidiary and demonstrated commercialization capabilities through two technology transfers.
Number of Employees
53people
Average Salary
71.3M KRW
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 15.004.0Point
PBR
0.86Industry Average 1.205.5Point
Lower than industry avg (good)
ROE
-76.22Industry Average 8.000.0Point
Well below industry avg
Debt Ratio
4.65Industry Average 100.008.0Point
Half of industry avg (excellent)
Trend 2023~20253.0 / 10 points
Revenue Growth Rate
3.0 / 3
Avg ▲547.5% (2-year basis)
Operating Profit Growth Rate
0.0 / 3
Avg ▼9.5% (2-year basis)
ROE Trend
0.0 / 4
Avg ROE -70.9% (declining, 3yr)
Detailed News Sentiment
0 totalPositive 0Neutral 0Negative 0
Detailed Momentum
52-week position8.0Point
Near 52w high (81%, uptrend)
Current 2,300Won52-week high 2,72052-week low 409
1-month return6.0Point
1m +350.98% (strong rise)
Volume trend1.0Point
Volume dry-up
Detailed Disclosure
5 totalPositive 0Neutral 5Negative 0
- Neutral주식등의대량보유상황보고서(일반)2026-10-07
- Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-10-07
- Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-10-07
- Neutral연결재무제표기준영업(잠정)실적(공정공시)2026-10-01
- Neutral주권매매거래정지해제 (액면병합 주권 변경상장)2026-09-28